

[Return to CIRM Meetings and Events](#)

Webinar: Immune Response in Stem Cell-based Therapy



Regenerative
Medicine
Consortium

Webinar: Immune Response in Stem Cell-based Therapy

Presentations from FDA and Leading Experts

Date: September 27, 2012 from 10 am to 12 noon (Pacific)

Below are links to recordings of the webinar as well as the speakers' slides:

Links to recordings of the webinar:

- Introduction by **moderator, Ellen Feigal**, MD, Senior VP of Research and Development, CIRM
- Recording of Webinar
- Transcript of Question and Answer Section

Links to the webinar speakers' presentation slides:

- Theresa Chen
- Heike Daldrop-Link
- Amitabh Gaur

Moderator: **Ellen Feigal**, MD, Senior Vice President of Research and Development, CIRM

Speakers:

- **Theresa Chen**, Ph.D., Pharmacology/Toxicology Reviewer, Office of Cellular, Tissue and Gene Therapies (OCTGT), Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA)
- **Heike Daldrop-Link**, M.D., Associate Professor of Radiology, Stanford University School of Medicine
- **Amitabh Gaur**, Ph.D., Director of Custom Technology, BD Biosciences

Topics covered:

- Presentation by FDA - regulatory perspective on immune rejection concerns in the preclinical assessment of human cellular therapy products
- Assessing immune response to stem cell transplants with clinically applicable imaging techniques
- Assessing the immunogenicity of stem cells
- Overcoming the immune rejection challenge
- Questions and Answers

Background material:

- CIRM held a Roundtable meeting on Immune Response with the FDA in October of 2011. Materials from that meeting are here.
 - In June 2010 CIRM committed \$25 million to overcome immune rejection of stem cell transplantation therapies. More information on the 19 awards in RFA 09-03, CIRM Stem Cell Transplantation Immunology Awards, can be found on our press release.
 - CIRM recently approved new awards related to the immune system:
 - Immune-Matched Neural Stem Cell Transplantation for Pediatric Neurodegenerative Disease
 - A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants
 - Mechanisms to protect hESC-derived cells from allogenic immune rejection
 - CIRM Video: Jeffrey Bluestone Talks About Immune Rejection of Stem Cell-Based Therapies
 - The American Association of Immunologists - Immunology 2012 Annual Meeting
-

Source URL: <http://www.cirm.ca.gov/agendas/12142012/webinar-immune-response-stem-cell-based-therapy>